References
- Born G. V. R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927–929
- Clarke R. J., Mayo G., Price P., Gerald G. A. Fitz. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137–1141
- DeWood M. A., Spores J., Notske R., Mouser L. T., Burroughs R., Golden M. S., Lang H. T. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897–902
- Hennekens C. H., Buring J. E., Sandercock P., Collins R., Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989; 80: 749–756
- ISIS-2. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988; 2: 349–360
- ISIS-3. A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753–770
- Küster L. J., Frölich J. C. Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man. Prostaglandins 1986; 32: 415–423
- Mueller H. S., Rao P. S., Greenberg M. A., Buttrick P. M., Sussman I. I., Levite H. A., Grose R. M., Perez-Davila V., Strain J. E., Spaet T. H. Systemic and transcardiac platelet activity in acute myocardial infarction in man: resistance to prostacyclin. Circulation 1985; 72: 1336–1345
- Naschitz J. E., Yeshurun D., Odeh M. Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease. Am J Gastroenterol 1991; 85: 408–411
- Nidorf S. M., Sturm M., Strophair J., Kendrew P. J., Taylor R. R. Whole blood aggregation, thromboxane release and the lyso derivative of platelet activating factor in myocardial infarction and unstable angina. Cardiovasc Res 1989; 23: 273–278
- Nyman I., Larsson H., Wallentin L., the Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia. Lancet 1992; 340: 497–501
- Patrono C., Ciabattoni G., Pinca E., Pugliese F., Castrucci G., De Salvo A., Satta M. A., Peskar B. A. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317–327
- Power I., Chambers W. A., Greer I. A. Platelet function after intramuscular diclofenac. Anaesthesia 1990; 45: 916–919
- Steering Committee of the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing Physicians' health study. N Engl J Med 1989; 321: 129–135
- The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–830
- Tselepis A. D., Tsoukatos D., Droudes C., Donas A., Evangelou A. Platelet response to the aggregatory effect of platelet activating factor (PAF) ex vivo in patients with acute myocardial infarction. Eur J Clin Invest 1991; 21: 490–496
- Vane R. J. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231: 232–235
- Verheugt F. W. A., Van der Laarse A., Funke-Küpper A. J., Sterkman L. G. W., Galema T. W., Roos J. P. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol 1990; 66: 267–270